Neurogene shares are trading lower. The company announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome.
Portfolio Pulse from Benzinga Newsdesk
Neurogene shares are trading lower after the company announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome.
June 18, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Neurogene shares are trading lower following the announcement of the first patient in Cohort 2 receiving high-dose NGN-401 gene therapy in the Phase 1/2 trial for Rett syndrome.
The announcement of the first patient in Cohort 2 receiving high-dose NGN-401 gene therapy in the Phase 1/2 trial for Rett syndrome has led to a decline in Neurogene's share price. Investors may be reacting to uncertainties or potential risks associated with the trial's outcomes.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100